Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Gridelli

Showing results (91-100 of 126) with videos related to

Pageof 13
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 1, 2005
Italian clinical research in non-small-cell lung cancerC Gridelli, A Rossi, D Galetta, et al.
Anticancer Research|January 29, 2000
Single-agent gemcitabine as second-line treatment in patients with advanced non small cell lung cancer (NSCLC): a phase II trialC Gridelli, F Perrone, C Gallo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 5, 2004
Treatment of advanced non-small-cell lung cancer patients with ECOG performance status 2: results of an European Experts PanelC Gridelli, A Ardizzoni, T Le Chevalier, et al.
Cancer|June 22, 1999
A Phase II study of gemcitabine in patients with malignant pleural mesothelioma. European Organization for Research and Treatment of Cancer Lung Cancer Cooperative GroupJ P van Meerbeeck, P Baas, C Debruyne, et al.
Lung Cancer (Amsterdam, Netherlands)|February 13, 2001
Activity and toxicity of gemcitabine and gemcitabine + vinorelbine in advanced non-small-cell lung cancer elderly patients: Phase II data from the Multicenter Italian Lung Cancer in the Elderly Study (MILES) randomized trialC Gridelli, S Cigolari, C Gallo, et al.
Seminars in Oncology|September 5, 1998
Gemcitabine as second-line treatment for relapsing or refractory advanced non-small cell lung cancer: a phase II trialL Crinò, A M Mosconi, G V Scagliotti, et al.
Current Medicinal Chemistry|June 6, 2012
The role of EGFR tyrosine kinase inhibitors in the first-line treatment of advanced non small cell lung cancer patients harboring EGFR mutationA Sgambato, F Casaluce, P Maione, et al.
Anticancer Research|May 16, 2000
Single agent docetaxel plus granulocyte-colony stimulating factor (G-CSF) in previously treated patients with advanced non small cell lung cancer. A phase II study and review of the literatureC Gridelli, L Frontini, E Barletta, et al.
British Journal of Cancer|January 5, 2001
Carboplatin plus paclitaxel in extensive small cell lung cancer: a multicentre phase 2 studyC Gridelli, L Manzione, F Perrone, et al.
Anticancer Research|March 1, 1997
A phase II study of VM-26 plus lonidamine in pretreated small cell lung cancerC Gridelli, F De Marinis, A Rossi, et al.
Pageof 13

Showing results (91-100 of 126) with videos related to

Sort By:
Pageof 13
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 1, 2005
Italian clinical research in non-small-cell lung cancerC Gridelli, A Rossi, D Galetta, et al.
Anticancer Research|January 29, 2000
Single-agent gemcitabine as second-line treatment in patients with advanced non small cell lung cancer (NSCLC): a phase II trialC Gridelli, F Perrone, C Gallo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 5, 2004
Treatment of advanced non-small-cell lung cancer patients with ECOG performance status 2: results of an European Experts PanelC Gridelli, A Ardizzoni, T Le Chevalier, et al.
Cancer|June 22, 1999
A Phase II study of gemcitabine in patients with malignant pleural mesothelioma. European Organization for Research and Treatment of Cancer Lung Cancer Cooperative GroupJ P van Meerbeeck, P Baas, C Debruyne, et al.
Lung Cancer (Amsterdam, Netherlands)|February 13, 2001
Activity and toxicity of gemcitabine and gemcitabine + vinorelbine in advanced non-small-cell lung cancer elderly patients: Phase II data from the Multicenter Italian Lung Cancer in the Elderly Study (MILES) randomized trialC Gridelli, S Cigolari, C Gallo, et al.
Seminars in Oncology|September 5, 1998
Gemcitabine as second-line treatment for relapsing or refractory advanced non-small cell lung cancer: a phase II trialL Crinò, A M Mosconi, G V Scagliotti, et al.
Current Medicinal Chemistry|June 6, 2012
The role of EGFR tyrosine kinase inhibitors in the first-line treatment of advanced non small cell lung cancer patients harboring EGFR mutationA Sgambato, F Casaluce, P Maione, et al.
Anticancer Research|May 16, 2000
Single agent docetaxel plus granulocyte-colony stimulating factor (G-CSF) in previously treated patients with advanced non small cell lung cancer. A phase II study and review of the literatureC Gridelli, L Frontini, E Barletta, et al.
British Journal of Cancer|January 5, 2001
Carboplatin plus paclitaxel in extensive small cell lung cancer: a multicentre phase 2 studyC Gridelli, L Manzione, F Perrone, et al.
Anticancer Research|March 1, 1997
A phase II study of VM-26 plus lonidamine in pretreated small cell lung cancerC Gridelli, F De Marinis, A Rossi, et al.
Pageof 13